title: Nicotinic acetylcholine receptor ligands, a patent review (2006-2011).
abstract: BACKGROUND
  Nicotinic acetylcholine receptors (nAChRs), pentameric ligand-gated cation channels, are potential targets for the development of therapeutics for a variety of disease states.
  
  
  METHODS
  This article is reviewing recent advances in the development of small-molecule ligands for diverse nAChR subtypes and is a continuation of an earlier review in this journal.
  
  
  CONCLUSIONS
  The development of nAChR ligands with preference for α4β2 or α7 subtypes for the treatment of central nervous system disorders are in the most advanced developmental stage. In addition, there is a fast growing interest to generate so-called PAMs, positive allosteric modulators, to influence the channels' functionalities.
authors.affiliation: University of Hawai'i at Hilo, College of Pharmacy, Department of Pharmaceutical Sciences, 34 Rainbow Drive, Hilo, HI 96720, USA. danielag@hawaii.edu
authors.forename: Daniela
authors.initials: D
authors.lastname: Gündisch
authors.forename: Christoph
authors.initials: C
authors.lastname: Eibl
mesh_terms: D000818:Animals; D002491:Central Nervous System Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D018678:Cholinergic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D015195:Drug Design; D006801:Humans; D008024:Ligands; D015394:Molecular Structure; D010330:Patents as Topic; D011978:Receptors, Nicotinic / Q000187:drug effects* / Q000378:metabolism; D013329:Structure-Activity Relationship
chemical_list: D002491:Central Nervous System Agents; D018678:Cholinergic Agents; D008024:Ligands; D011978:Receptors, Nicotinic
references.citation: Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1241-8
references.pmid: 11158624
references.citation: J Pharmacol Exp Ther. 2000 Sep;294(3):1112-9
references.pmid: 10945867
references.citation: Am J Med Genet. 2001 Dec 8;105(8):655-7
references.pmid: 11803510
references.citation: Annu Rev Pharmacol Toxicol. 2007;47:699-729
references.pmid: 17009926
references.citation: Psychopharmacology (Berl). 1992;107(2-3):285-9
references.pmid: 1615127
references.citation: J Neurobiol. 2002 Dec;53(4):431-46
references.pmid: 12436411
references.citation: Biol Psychiatry. 1995 Jul 1;38(1):22-33
references.pmid: 7548469
references.citation: Trends Pharmacol Sci. 2010 Dec;31(12):580-6
references.pmid: 20965579
references.citation: Neuropharmacology. 2010 Mar-Apr;58(4-5):806-15
references.pmid: 20004675
references.citation: J Neurochem. 2000 Jan;74(1):237-43
references.pmid: 10617125
references.citation: Psychiatr Clin North Am. 2003 Mar;26(1):25-40
references.pmid: 12683258
references.citation: Neuropharmacology. 2008 Jun;54(8):1189-200
references.pmid: 18448138
references.citation: Biochem Pharmacol. 2009 Oct 1;78(7):844-51
references.pmid: 19555668
references.citation: J Physiol. 2010 Feb 15;588(Pt 4):597-602
references.pmid: 19917567
references.citation: J Neurosci. 2005 Nov 23;25(47):10905-12
references.pmid: 16306403
references.citation: Nat Rev Neurosci. 2002 Feb;3(2):102-14
references.pmid: 11836518
references.citation: Mol Pharmacol. 2004 Jun;65(6):1526-35
references.pmid: 15155845
references.citation: Psychopharmacology (Berl). 2003 Feb;165(4):386-96
references.pmid: 12459928
references.citation: CNS Neurosci Ther. 2008 Winter;14(4):266-77
references.pmid: 19040552
references.citation: Biochem Pharmacol. 2011 Oct 15;82(8):1015-21
references.pmid: 21640716
references.citation: Br J Pharmacol. 2008 Feb;153(4):792-804
references.pmid: 18059317
references.citation: Schizophr Res. 2005 Jul 1;76(1):67-72
references.pmid: 15927799
references.citation: Curr Pharm Des. 2011;17(14):1343-50
references.pmid: 21524268
references.citation: Nat Rev Cancer. 2009 Mar;9(3):195-205
references.pmid: 19194381
references.citation: Nature. 1970 Dec 5;228(5275):917-22
references.pmid: 4921376
references.citation: J Neurobiol. 2002 Dec;53(4):641-55
references.pmid: 12436427
references.citation: J Med Chem. 2008 Feb 28;51(4):701-12
references.pmid: 18198823
references.citation: Trends Mol Med. 2008 Mar;14(3):93-102
references.pmid: 18262468
references.citation: Neuropsychopharmacology. 2010 May;35(6):1391-401
references.pmid: 20147893
references.citation: Acta Paediatr. 2006 Jun;95(6):645-9
references.pmid: 16754543
references.citation: Oncogene. 2010 Sep 2;29(35):4874-84
references.pmid: 20581870
references.citation: Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13206-11
references.pmid: 20616056
references.citation: Curr Pharm Des. 2010 Jan;16(3):323-43
references.pmid: 20109142
references.citation: J Neurochem. 2011 Mar;116(5):734-41
references.pmid: 21214570
references.citation: Clin Neuropharmacol. 2002 Sep-Oct;25(5):272-5
references.pmid: 12410061
references.citation: Curr Pharm Des. 2006;12(4):407-28
references.pmid: 16472136
references.citation: Neuropharmacology. 2007 Apr;52(5):1256-62
references.pmid: 17320916
references.citation: Nature. 1998 Jan 8;391(6663):173-7
references.pmid: 9428762
references.citation: Biochem Pharmacol. 1999 Sep 15;58(6):917-23
references.pmid: 10509744
references.citation: Biochem Pharmacol. 2010 Oct 15;80(8):1238-51
references.pmid: 20599770
references.citation: Drug Saf. 2010 Apr 1;33(4):289-301
references.pmid: 20297861
references.citation: Expert Opin Ther Pat. 2011 Dec;21(12):1867-96
references.pmid: 22098319
references.citation: Nature. 2009 Mar 26;458(7237):534-7
references.pmid: 19252481
references.citation: Biochem Pharmacol. 2011 Oct 15;82(8):800-7
references.pmid: 21787755
references.citation: Pharm Acta Helv. 2000 Mar;74(2-3):103-14
references.pmid: 10812946
references.citation: Biochem Pharmacol. 2009 Oct 1;78(7):703-11
references.pmid: 19481063
references.citation: J Physiol Paris. 1998 Jun-Aug;92(3-4):221-4
references.pmid: 9789812
references.citation: Biochem Pharmacol. 2011 Oct 15;82(8):915-30
references.pmid: 21575610
references.citation: Curr Pharm Des. 2011;17(17):1652-62
references.pmid: 21619531